Business Context and Reporting Period
Company: Coherus Oncology, Inc. (CHRS)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2026
Business Overview: Coherus is a commercial-stage innovative oncology company focused on its approved PD-1 inhibitor, LOQTORZI (toripalimab-tpzi), and a pipeline of two mid-stage clinical candidates (casdozokitug and tagmokitug). The company has divested its biosimilar businesses (UDENYCA, YUSIMRY, CIMERLI), which are now reported as discontinued operations.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Revenue (Continuing) | $12,310 | $7,599 |
| Net Revenue (Discontinued) | $(899) | $32,134 |
| Cost of Goods Sold | $3,814 | $2,653 |
| Gross Margin | 69% | 65% |
| Research & Development | $21,543 | $24,356 |
| Selling, General & Admin | $23,104 | $26,025 |
| Net Loss (Continuing) | $(36,935) | $(47,398) |
| Net Loss (Total) | $(38,327) | $(56,569) |
| Cash & Cash Equivalents | $115,238 | $88,879 |
| Marketable Securities | $51,810 | $83,246 |
| Total Liquidity | $167,048 | $172,125 |
| Term Loan (Non-current) | $37,147 | $37,051 |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue from continuing operations increased 62% year-over-year to $12.3 million, driven primarily by volume growth of LOQTORZI. Gross margin improved to 69% from 65%.
- Expense Reduction: R&D expenses decreased by $2.8 million (12%) and SG&A expenses decreased by $2.9 million (11%), attributed to lower headcount and reduced operating costs following the exit from the biosimilar business.
- Discontinued Operations: Net loss from discontinued operations improved significantly to $(1.4) million from $(9.2) million, reflecting the completion of the UDENYCA sale in April 2025 and the absence of prior-year derivative liability charges.
- Capital Raise: The company completed a public offering in February 2026, issuing 32.89 million shares and raising net proceeds of $53.6 million.
- Inventory Capitalization: The company commenced capitalizing inventory costs for LOQTORZI produced in the U.S. during Q1 2026 following regulatory approval of the manufacturing process.
Guidance, Outlook, and Risks
- Outlook: Management expects net revenue from continuing operations in 2026 to be higher than in 2025 due to continued LOQTORZI growth. Fixed R&D and SG&A expenses are expected to be lower in 2026 compared to 2025.
- Liquidity: As of March 31, 2026, the company held $167.0 million in cash, cash equivalents, and marketable securities. Management believes this is sufficient to fund operations for at least the next 12 months.
- Key Risks:
- Profitability: The company has a limited history of profitability and an accumulated deficit of $1.4 billion. Future profitability depends on LOQTORZI sales growth and the success of pipeline candidates.
- Competition: LOQTORZI faces significant competition in the nasopharyngeal carcinoma (NPC) market from established anti-PD-1/PD-L1 therapies and new entrants (e.g., Penpulimab approved in April 2025).
- Regulatory & Manufacturing: Risks include FDA disruptions, manufacturing supply chain issues, and the transition of biomanufacturing from offshore to onshore facilities.
- Healthcare Reform: The Inflation Reduction Act (IRA) and the One Big Beautiful Bill Act (OBBBA) may impact pricing, reimbursement, and Medicaid funding.
- Contingencies: The company is eligible for two potential earnout payments of $37.5 million each from the UDENYCA sale, contingent on future net sales thresholds.
Investor Verification Checklist
- LOQTORZI Sales Trajectory: Verify the sustainability of the 62% revenue growth rate and market share gains in the NPC indication against competitors.
- Cash Burn Rate: Assess the net cash used in operating activities ($57.9 million in Q1 2026) against the $167 million liquidity position to confirm the 12-month runway.
- Manufacturing Transition: Monitor the progress and cost implications of onshoring biomanufacturing for LOQTORZI and pipeline candidates.
- Pipeline Milestones: Track clinical progress for casdozokitug (HCC) and tagmokitug (HNSCC, mCRPC) and potential ex-U.S. licensing deals.
- UDENYCA Earnouts: Evaluate the likelihood of achieving the $300 million and $350 million net sales thresholds required for the $75 million in potential earnout payments.